The outlook of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the loss of exclusivity in key markets has introduced substantial volatility. Investors are now grappling with the effect of lower-cost alter